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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to provide a supplementary dietary exposure and safety assessment of
synthetic L-ergothioneine for those groups of the population which had been excluded by the applicant
in the original application, i.e. infants and young children (i.e. toddlers), pregnant and breastfeeding
women. Thus, intake estimates were calculated for these population groups and the following
maximum anticipated daily intakes of L-ergothioneine from the NF, in addition to the background diet,
were calculated: 2.82 mg/kg body weight (bw) per day for infants, 3.39 mg/kg bw per day for
toddlers and 1.31 mg/kg bw per day for adults including pregnant and breastfeeding women. The
Panel considers that based on the overall toxicological data the no-observed-adverse-effect level
(NOAEL) of 800 mg/kg bw per day as established in the original assessment also pertains to pregnant
and breastfeeding women as well as to young children (i.e. toddlers) and infants. The corresponding
margins of exposure (i.e. the ratio between the NOAEL and the maximum anticipated daily intakes)
are 284 for infants, 236 for young children and 610 for pregnant and breastfeeding women. These
margins of exposure are considered sufﬁcient. The Panel concludes that the novel food, synthetic
L-ergothioneine, is safe under the proposed uses and use levels for infants, young children (i.e.
toddlers) and pregnant and breastfeeding women.
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of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to provide a supplementary dietary exposure and safety assessment for
synthetic L-ergothioneine for infants and young children, pregnant and breastfeeding women.
In 2016, the EFSA NDA Panel assessed the safety of synthetic L-ergothioneine as a novel food (NF)
pursuant to Regulation (EC) No 258/97, and a Scientiﬁc Opinion was adopted on 26 October 2016. In
performing the safety assessment of the NF, the NDA Panel considered the proposed uses (as a food
ingredient added to alcohol-free beverages, milk, ‘fresh’ dairy products, cereal bars and chocolate; and
as a food supplement) and the proposed target population, i.e. children above 3 years of age and the
general adult population, with the exception of pregnant and breastfeeding women. Taking into
account a no-observed-adverse-effect level (NOAEL) of 800 mg/kg body weight (bw) per day and the
maximum estimated intake levels for L-ergothioneine from all sources (i.e. fortiﬁed foods, food
supplements and background diet), in 2016, the Panel concluded that the margins of safety of 470 for
adults (excluding pregnant and breastfeeding women) and of 216 for children above 3 years of age
are sufﬁcient.
In 2017, some Member States raised concerns about the potential for exposure of the excluded
population subgroups to the NF from the consumption of products containing the NF, since in real life
situations it would be difﬁcult to ensure that those products (e.g. chocolate, dairy products) will not be
consumed by the excluded subgroups.
In consequence, the European Food Safety Authority (EFSA) was asked to carry out a
supplementary dietary exposure and safety assessment for L-ergothioneine for those groups of the
population, i.e. infants and young children, pregnant and breastfeeding women, not considered in the
previous assessment.
In order to derive intake estimates for these population groups, a reﬁned intake assessment was
performed by EFSA using the EFSA Comprehensive European Food Consumption Database, which is
based on data from EU dietary surveys.
Food supplements as a source of the NF are not considered for the combined intake for these
population groups, since for food supplements labelling is considered an effective means to restrict
consumption by the target population (i.e. children above 3 years of age and adults excluding
pregnant and breastfeeding women) of the NF. Moreover, no separate intake assessment was
performed for pregnant and breastfeeding women, as consumption data for this population group are
not available. However, it is considered that the expected intake of pregnant and breastfeeding women
falls within the intake estimates calculated for the general adult population.
Combined intake estimates were calculated for L-ergothioneine from foods fortiﬁed with the NF and
for naturally occurring L-ergothioneine from the background diet and maximum anticipated daily
intakes were calculated as 2.82 mg/kg bw per day for infants, 3.39 mg/kg bw per day for toddlers and
1.31 mg/kg bw per day for adults including pregnant and breastfeeding women.
The Panel considers that based on the overall toxicological data the NOAEL of 800 mg/kg bw per
day as established in the original assessment also pertains to pregnant and breastfeeding women as
well as to young children (i.e. toddlers) and infants.
The corresponding margins of exposure (i.e. the ratio between the NOAEL and the maximum
anticipated daily intakes) are 284 for infants, 236 for young children and 610 for pregnant and
breastfeeding women. These margins of exposure are considered sufﬁcient.
The Panel concludes that the NF, synthetic L-ergothioneine, is safe under the proposed uses and
use levels for infants, young children (i.e. toddlers) and pregnant and breastfeeding women.
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1. Introduction
1.1. Background
On 26 October 2016, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) adopted
the Scientiﬁc Opinion on the safety of synthetic L-ergothioneine as a novel food (NF) pursuant to
Regulation (EC) No 258/971 (EFSA NDA Panel, 2016).
In its opinion, the NDA Panel concluded that the NF, synthetic L-ergothioneine, is safe under the
intended conditions of use as speciﬁed by the applicant, i.e. the NF to be added to various food
groups (i.e. alcohol-free beverages, milk, ‘fresh’ dairy products, cereal bars and chocolate) and to be
used as a food supplement. The target population was children above 3 years of age and the general
adult population, with the exception of pregnant and breastfeeding women.
At the Standing Committee meeting held in March 2017, some Member States raised concerns
about the potential for exposure of the excluded population subgroups to L-ergothioneine from the
consumption of products containing L-ergothioneine. These Member States argued that although
the use of L-ergothioneine has been assessed by EFSA to be safe for the intended uses as set out in
the application, in real life situations it would be difﬁcult to ensure that those products (e.g. chocolate,
dairy products) will not be consumed by the excluded subgroups.
In consequence, it was decided that an exposure and safety assessment was needed for these
excluded subgroups for additional reassurance.
1.2. Terms of Reference as provided by the requestor
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission
asked the European Food Safety Authority to carry out a supplementary dietary exposure and safety
assessment for L-ergothioneine for those groups of the population (infants and young children,
pregnant and breastfeeding women) excluded by the applicant, as a novel food ingredient in the
context of Regulation (EC) No 258/97.
2. Data and methodologies
2.1. Data
The supplementary dietary exposure and safety assessment of synthetic L-ergothioneine for infants
and young children, pregnant and breastfeeding women is based on the data provided in the original
NF application (i.e. Dossier ‘Tetrahedron Ergoneine Documentation February conﬁdential’), additional
information submitted by the applicant in the context of the original application, and on the published
Scientiﬁc Opinion on the safety of synthetic L-ergothioneine as a novel food (EFSA NDA Panel, 2016).
For the supplementary intake assessment, the EFSA Comprehensive European Food Consumption
Database was used (EFSA, 2011).
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
On 26 October 2016, the EFSA NDA Panel adopted the Scientiﬁc Opinion on the safety of synthetic
L-ergothioneine as a novel food (NF) pursuant to Regulation (EC) No 258/97 (EFSA NDA Panel, 2016).
In performing the safety assessment of the NF, the NDA Panel considered the proposed uses (i.e.
food ingredient added to alcohol-free beverages, milk, ‘fresh’ dairy products, cereal bars and
chocolate; food supplements) and the proposed target population (i.e. children above 3 years of age
and the general adult population, with the exception of pregnant and breastfeeding women).
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
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Detailed information on the safety assessment of synthetic L-ergothioneine is provided in the
published opinion (EFSA NDA Panel, 2016), which informs on the speciﬁcations of the NF, its stability,
the production process, the anticipated intake/extent of use in the proposed target population,
nutritional information of the NF, microbiological information, toxicological information (including
absorption, distribution, metabolism and excretion), human studies and potential allergenicity of the
NF.
In 2016, the NDA Panel considered a no-observed-adverse-effect level (NOAEL) of 800 mg/kg body
weight (bw) per day of the NF. Taking into account this NOAEL and the maximum estimated intake
levels for L-ergothioneine from all sources (i.e. fortiﬁed foods, food supplements and background diet)
of 1.7 mg/kg bw per day for adults and of 3.7 mg/kg bw per day for children, the Panel concluded
that the margins of safety of 470 for adults (excluding pregnant and breastfeeding women) and of 216
for children above 3 years of age are sufﬁcient.
The scope of this scientiﬁc statement is to provide a supplementary dietary exposure and safety
assessment of the NF for those groups of the population which had not been considered in the original
safety assessment, i.e. infants and young children, pregnant and breastfeeding women.
3.1. Anticipated intake/extent of use
It is noted that the intended uses and use levels for the NF remain the same as in the original
application, i.e. the applicant intends to use the NF in alcohol-free beverages, milk, ‘fresh’ dairy
products (e.g. cream, cream cheese and yoghurts), cereal bars and chocolate (Table 1).
A quantity of up to 5 mg NF per serving of these foods was proposed. In order to achieve this
quantity, the different food categories are proposed to be fortiﬁed with the NF at various use levels as
indicated in Table 1, taking into account the various portion sizes of the foods. The indicated use levels
represent the maximum use levels in the speciﬁed food groups.
The applicant also proposes to market the NF as a food supplement, with a recommended daily
dose of up to 30 mg/day for adults excluding pregnant and breastfeeding women and 20 mg/day for
children from 3–17 years.
Food supplements as a source of the NF are not considered for the population groups under
evaluation for this statement, since for food supplements labelling is considered an effective means to
restrict consumption by the target population (i.e. children above three years of age and adults
excluding pregnant and breastfeeding women).
3.1.1. Intake from fortiﬁed foods
In order to derive intake estimates for the population groups under evaluation a reﬁned intake
assessment was performed by EFSA using the EFSA Comprehensive European Food Consumption
Database (EFSA, 2011), which is based on data from EU dietary surveys.
The food categories for the proposed use of the NF were allocated to corresponding food
categories of the EFSA Comprehensive Food Consumption Database (EFSA, 2011) as indicated in
Table 2.
Table 1: Proposed uses and maximum use levels of the NF as a food ingredient
Food category
Maximum use level
of the NF (mg/kg)
Mean portion
size
Alcohol-free beverages 25 200 mL
Milk 25 200 mL
‘Fresh’ dairy products 40 125 g
Cereal bars 200 25 g
Chocolate 250 20 g
Safety of L-ergothioneine in infants, young children, pregnant and breastfeeding women
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Mean and high (i.e. 95th percentile) intake estimates were calculated for infants, young children
(i.e. toddlers) and adults (including pregnant and breastfeeding women), assuming that the foods
contain the NF at the maximum proposed use levels.
No separate intake assessment was performed for pregnant and breastfeeding women, as
consumption data for this population group are not available. However, it is considered that the
expected intake of pregnant and breastfeeding women falls within the intake estimates calculated for
the general adult population.
The ranges of the estimated mean and high intakes (in mg/kg bw per day) among the individual
EU dietary surveys for the various population groups are presented in Table 3.
3.1.2. Intake from the background diet
As described in the published opinion (EFSA NDA Panel et al., 2016), the foods with the highest
natural L-ergothioneine content are mushrooms, which account for about 95% of naturally occurring
L-ergothioneine intake via the diet.
Based on the available data, highest chronic exposures to natural L-ergothioneine were found for
Italy for both population groups, adults and children.
For Italian adults, a mean and high (95th percentile) consumption of 0.06 and 0.48 mg/kg bw per
day, respectively, was derived for the total population. In the population of consumers, mean and high
consumptions amount to 0.22 and 0.70 mg/kg bw per day, respectively.
For the population of Italian children, a mean and high consumption of 0.06 and 0.64 mg/kg bw
per day, respectively, was calculated for the total population, with a mean and high consumption for
consumers of 0.41 and 1.11 mg/kg bw per day, respectively.
3.1.3. Combined intake from fortiﬁed foods and the background diet
Combined intake estimates were calculated for L-ergothioneine (synthetic and natural) from foods
fortiﬁed with the NF and from the background diet.
A conservative approach was taken, summing up the highest 95th percentile intakes from fortiﬁed
foods for each population group with the highest 95th percentile of intake of naturally occurring L-
ergothioneine from the background diet (Table 4).
Table 2: Proposed uses and maximum use levels of the NF as a food ingredient considering the
food categories of the EFSA Comprehensive Food Consumption Database
Food category used for the EFSA Comprehensive Data Base
Use levels
(mg/kg)
Flavoured drinks with sugar 25
Flavoured drinks with sweetener 25
Unﬂavoured pasteurised and sterilised (including UHT) milk 25
Cream and cream powder 40
Flavoured fermented milk products including heat-treated products 40
Unﬂavoured fermented milk products, including natural unﬂavoured buttermilk (excluding sterilised
buttermilk) non heat-treated after fermentation
40
Cereal bars 200
Cocoa and chocolate products 250
Table 3: Intake estimates of the NF from foods fortiﬁed with the NF at the maximum proposed use
levels
Population group
Range of means
(mg/kg bw per day)
Range of high intakes
(95%)(a) (mg/kg bw per day)
Infants (up to 1 year) 0.11–1.39 0.40–2.82
Toddlers (i.e. young children) (1–3 years) 0.74–1.14 1.73–2.28
Adults (18–64 years) including pregnant
and breastfeeding women
0.07–0.25 0.19–0.61
bw: body weight.
(a): Based on surveys with >60 consumers
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4. Discussion
In the original dossier, a NOAEL of 800 mg/kg bw per day of the NF was identiﬁed based on a
90-day toxicity study (according to OECD Test Guideline (TG) 408). In addition, in a screening test for
reproductive and developmental toxicity (according to OECD TG 422), no effects of the NF on any
parameter of reproductive or developmental toxicity were noted.
The Panel considers that based on the overall toxicological data the NOAEL of 800 mg/kg bw per
day as established in the original assessment also pertains to pregnant and breastfeeding women as
well as to toddlers (i.e. young children) and infants.
The maximum anticipated daily intakes of L-ergothioneine from the NF, in addition to the
background diet, for infants, toddlers and adults including pregnant and breastfeeding women are
2.82, 3.39 and 1.31 mg/kg bw per day, respectively.
The corresponding margins of exposure (i.e. the ratio between the NOAEL and the maximum
anticipated daily intakes) for the different population groups are presented in Table 5.
The Panel notes the margins of exposure of 284 for infants, 236 for toddlers and 610 for pregnant
and breastfeeding women.
These population groups can reasonably be expected not to consume the NF as a food supplement
owing to labelling provisions.
The intake estimates are based on the conservative assumption that all proposed food items
consumed by an individual contain the NF at the maximum proposed use levels. These estimates also
consider high chronic intake of naturally occurring L-ergothioneine via the background diet, with the
exception of infants, who are not expected to consume mushrooms (i.e. the main source of naturally
occurring L-ergothioneine) to a signiﬁcant extent with their diet.
The Panel considers that the margins of exposure for the NF at the intended uses and use levels
are sufﬁcient for infants, young children (i.e. toddlers) and pregnant and breastfeeding women.
5. Conclusions
The Panel concludes that the novel food, synthetic L-ergothioneine, is safe under the proposed uses
and use levels for infants, young children (i.e. toddlers) and pregnant and breastfeeding women.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request to carry out a supplementary dietary exposure and safety assessment to
L-ergothioneine. Ref. Ares(2017)2555205, dated 19/5/2017.
Table 4: Combined intake estimates (in mg/kg bw per day) for L-ergothioneine
Population group
Fortiﬁed foods95th
percentile
Background diet95th
percentile
Combined intake
Infants (up to 1 year) 2.82 – (a) 2.82
Toddlers (1–3 years) 2.28 1.11 3.39
Adults including pregnant and
breastfeeding women
0.61 0.70 1.31
(a): In infants, the intake of L-ergothioneine via the background diet is considered negligible, as infants are not expected to
consume mushrooms to a signiﬁcant extent.
Table 5: Margins of exposure between the NOAEL (i.e. 800 mg/kg bw per day) and the combined
intake estimates
Population group
Maximum anticipated intake
(mg/kg bw per day)
Margin of
exposure
Infants (up to 1 year)(a) 2.82 284
Toddlers (1–3 years) 3.39 236
Pregnant and breastfeeding women 1.31 610
bw: body weight.
(a): The NF is not intended to be added to infant formula.
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